Myeloid Therapeutics

Myeloid Therapeutics is an immunology company focused on combining biology insights with cutting-edge technologies to harness myeloid cells and eradicate cancer and other diseases. We’re passionate about scientific inquiry, collaborating to solve big clinical problems, and most of all, helping patients. Myeloid is powered by our founders – a group of world-leading scientists whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery. And we are working to build a team of talented, driven scientists and other biotech industry experts, who will turn these discoveries into novel, lifesaving treatments for patients. Our ATAKTM platform integrates the accumulated know-how and experience of our founders and our growing research team, to deliver new products that reprogram innate immune cells to eradicate disease. We have built a platform manufacturing process that reduces cell handling to less than one day, and supports the rapid translation of the company’s lead assets to the clinic: MT-101 for peripheral and cutaneous forms of T cell Lymphoma, MT-102 for HER2 expressing solid tumors, MT-103 for TROP2 expressing solid tumors, and MT-201, our primed monocyte that stimulates T cells to fight glioblastoma. We expect to initiate clinical trials for several of these product candidates in the first half of 2021, a mere 18-months from our founding. We invite you to join us on this journey – patients are waiting. – Daniel Getts, CEO